MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record ...
December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and ...
MELBOURNE, Australia, March 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the ...
March 2025 Quarter AUD$0.5 million up 28% on prior year March 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; ...
Immuron announces interim topline results from Travelan; to proceed to phase 3 clinical trials in US
Immuron Limited, an Australian-based and globally integrated biopharmaceutical company, has announced the interim topline results confirming that a single daily dose of Travelan is effective in ...
Strong continued growth of Travelan® sales reported in all markets North American Travelan® sales up by 98% YoY in the first half of FY20 Immuron achieved 55% YoY growth for the first half of FY20, ...
MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it ...
Immuron Ltd (ASX:IMC, NASDAQ:IMRN) is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. Australian-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results